Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
364 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Show all (35)
  • Currently Recruiting (11)
  • (-) Closed (24)

Medical Condition

  • Show all (1565)
  • Addiction (14)
  • Allergy, Asthma, & Immunology (11)
  • All of Us Research Program - NIH (1)
  • Autoimmune Disorders (26)
  • Blood Disorders (37)
  • Bone & Muscle (8)
  • Cancer (640)
    • Bladder Cancer (12)
    • (-) Brain Cancer (15)
    • Breast Cancer (64)
    • Gastrointestinal (13)
    • Gynecologic Cancer (24)
    • Head and Neck Cancer (4)
    • Kidney Cancer (7)
    • Leukemia (71)
    • (-) Liver Cancer (9)
    • Lung Cancer (59)
    • Lymphoma (34)
    • Multiple Myeloma (23)
    • Pancreatic Cancer (15)
    • Prostate Cancer (30)
    • Sarcoma (25)
    • Skin Cancer (28)
    • Solid Tumors (44)
    • Thyroid Cancer (1)
    • Uveal Melanoma (7)
  • Child Development (3)
  • COVID-19 (Coronavirus) (27)
  • Critical Illness (1)
  • Dental (2)
  • Developmental Disorders (2)
  • Diabetes (13)
  • Ear, Nose and Throat (5)
  • Endocrine & Metabolic Disease (11)
  • Eye (8)
  • Gastrointestinal and Digestive Diseases (19)
  • Hair and Skin Disorders (1)
  • Headaches (5)
  • Healthy Volunteers (131)
  • Heart Disease (104)
  • Infectious Disease (37)
  • Insomnia (2)
  • Kidney Disease (12)
  • Liver Disease (35)
  • Lung Disease (29)
  • Meniere's Disease (1)
  • Neurological Disorders (131)
  • Nutrition (3)
  • Obesity (2)
  • Obstetrics & Gynecology (40)
  • Pain Management (1)
  • Pediatrics (78)
  • Psychiatric Disorders (57)
  • Rehabilitation (7)
  • Stroke (5)
  • Surgery (7)
  • Transplant (36)
  • Urology (4)
  • Vascular Conditions (9)
Displaying 1 - 24 of 24

Study of Radiosurgery & Nivolumab Alone or in Combination with Ipilimumab in Patients with Meningioma

Condition: Cancer / Brain Cancer
Investigator: Aya Haggiagi, MD
Status: Closed
Phase 2, Treatment A: This study is being done to see if your recurrent brain tumor may respond to a combination of radiosurgery (a type of radiation therapy) with nivolumab (a type of immunotherapy drug). A small number of patients have already received this combination previously and have tolerated the treatment relatively well. However, we would like to…
Read More

Study of Vismodegib and GSK2256098 to Shrink Tumors in Patients with Meningioma

Condition: Cancer / Brain Cancer
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to test good and bad effects of these two different drugs against meningioma tumors with altered genes. Today, therapy for meningioma is the same for all patients and is not based on tumor genetic testing. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients with meningioma.…
Read More

Study of Atezolizumab and Bevacizumab Alone or in Combination with Tiragolumab in Patients with Hepatocellular Carcinoma (HCC)

Condition: Cancer / Liver Cancer
Investigator: Linda Wu, MD
Status: Closed
The purpose of this study is to compare the effects, good or bad, of tiragolumab plus atezolizumab plus bevacizumab versus placebo plus atezolizumab plus bevacizumab on patients with HCC. In this study, participants will be randomized you will get either tiragolumab plus atezolizumab plus bevacizumab or placebo plus atezolizumab plus bevacizumab. A placebo…
Read More

Study of REC-2282 in Patients with Progressive NF2 Mutated Meningiomas

Condition: Cancer / Brain Cancer
Investigator: Gurcharanjeet Kaur, MD
Status: Closed
The purpose of this study is to find out if REC-2282, an investigational new drug, is an effective and safe treatment in patients with progressive NF2 mutated meningiomas who have either NF2 disease-related meningioma or recurrent sporadic meningiomas that have NF2 mutation. Investigational new drug means a drug that has not been approved as a marketed…
Read More

Study of Safusidenib in Patients with Brain Glioma

Condition: Cancer / Brain Cancer
Investigator: Fabio Iwamoto, MD
Status: Closed
The purpose of this study is to see how safe and effective Safusidenib erbumine, the study drug, is in treating brain glioma and to find the recommended dose of the study drug for clinical studies. Safusidenib is not Food and Drug Administration (FDA) approved.
Read More

Study of Immune Therapy Drugs in Addition to the Usual Radiation Therapy for Patients with Brain Cancer (Glioblastoma)

Condition: Cancer / Brain Cancer
Investigator: Fabio Iwamoto, MD
Status: Closed
This study is being done to answer the following question: Can we shrink or stabilize your brain cancer by adding immune therapy drugs to the usual radiation therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your recurrent glioblastoma. The usual approach is defined as care most…
Read More

Study of Vaccine for Cytomegalovirus (CMV) in Patients with Brain Tumors

Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to test the safety of a new vaccine, VBI-1901, and to know more about its ability to boost the response of the immune system against Cytomegalovirus. The reason for testing this vaccine in people with a brain tumor is that it might one day be used to boost the ability of the immune system to fight a certain type of brain tumor.…
Read More

Study of DSP-0390 in Patients with Recurrent High-Grade Glioma

Condition: Cancer / Brain Cancer
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to evaluate how safe the investigational drug, DSP-0390, is at different doses and to identify a recommended dose that is safe for further study. Investigational means that the study drug is currently being tested and has not been approved for use alone or in combination with any drug by the U.S. Food and Drug Administration (…
Read More

ImmuneSense Study: IGV-001 in Newly Diagnosed Patients With Glioblastoma

Condition: Cancer / Brain Cancer
Investigator: Brian Gill, MD
Status: Closed
The purpose of this study is to see how safe the study medicine, IGV-001 plus standard of care (SOC), is and to compare IGV-001 with a placebo see if it works in slowing glioblastoma multiforme (GBM) tumor regrowth. SOC refers to the usual medicine(s) or procedures used to treat your cancer. A placebo looks like the study medicine but does not contain any…
Read More

Study of Pemigatinib in Patients with Glioblastoma (GBM) or Other CNS Tumors

Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to evaluate and determine the efficacy of pemigatinib in participants with recurrent glioblastoma or other CNS tumors with changes in the FGFR1, FGFR2 or FGFR3 genes. Pemigatinib (also referred as INCB054828) is an investigational drug that is being studied by Incyte Corporation (Sponsor) for use in the treatment of previously…
Read More

Study of Tumor Treating Fields (Optune, 200kHz) with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Condition: Cancer / Brain Cancer
Investigator: Fabio Iwamoto, MD
Status: Closed
Optune is a portable, battery-operated device that generates TTFields at a specific frequency. The TTFields are delivered to the brain through 4 sticky bandages (which hold ceramic discs) that are placed on the surface of the head (called arrays). The arrays create electric forces within the brain that disrupt cancer cell division. Optunes TTFields are a…
Read More

Study of MTX110 in Combination with Gadolinium in Children & Young Adults with Newly Diagnosed Brain Cancer (Diffuse Midline Gliomas)

Condition: Cancer / Brain Cancer
Investigator: James Hinkley Garvin Jr, MD
Status: Closed
The purpose of this study is to find the best dose of a drug called MTX110 and a contrast agent called gadolinium that can be given safely in children with newly diagnosed diffuse midline gliomas, which is a kind of brain tumor. All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered with a pump directly into the tumor…
Read More

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this research study is to see if the combination of medications approved for the treatment of glioblastoma, together with the study drug, selinexor (also known as XPOVIO), has any effects on your cancer. Selinexor works by trapping tumor suppressor proteins within the cell nucleus. This is expected to cause the cancer cells to die or stop…
Read More

Study of AG-881 in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
This study is being done to evaluate the safety and usefulness of the study drug, AG-881, as compared to placebo (a medically inactive substance) in residual or recurrent non-enhancing Grade 2 glioma (a type of brain cancer) that has a mutation in the IDH1 or IDH2 metabolic enzyme (a substance produced by the body to assist in breaking down chemicals).…
Read More

Study of ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this research study is to test how safe and how well an investigational drug known as ONC201 works in treating high grade glioma (a type of brain cancer). The FDA (the U.S. Food and Drug Administration) has not approved ONC201 as a treatment for this condition.
Read More

Study for Patients with Anaplastic Astrocytoma That Progress/Recur After Radiation and Chemotherapy

Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy. Safety and how well you can tolerate the drug will be determined on the basis of physical exams, laboratory tests,…
Read More

A Study of Atezolizumab Plus Bevacizumab Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence

Condition: Cancer / Liver Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to compare the effects, good or bad, of atezolizumab plus bevacizumab versus observation (not receiving any treatment) on patients with completely resected (surgically removed) or ablated (removed using heat) hepatocellular carcinoma (the most common type of liver cancer) who are at high risk for disease recurrence.…
Read More

A Study of Atezolizumab in Combination with Cobimetinib Versus Atezolizumab Monotherapy in Participants with Unresectable Cholangiocarcinoma

Condition: Cancer / Liver Cancer
Investigator: Susan Bates, MD
Status: Closed
The purpose of this study is to compare any good and bad effects of using atezolizumab alone or with another drug called cobimetinib. About 82 people are expected to taking part in this study. Adding cobimetinib to atezolizumab could help to shrink your cancer, but it could also cause extra side effects. This study will allow the researchers to know whether…
Read More

A study for patients with advanced hepatocellular carcinoma using study drug pembrolizumab

Condition: Cancer / Liver Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to test the safety, tolerability, and anti-tumor activity of the research study drug, Pembrolizumab (also known as MK-3475) in subjects with advanced hepatocellular carcinoma (a type of liver cancer also referred to as HCC) who have taken sorafenib.
Read More

Study of Drug in Patients with Previously Treated Bile Duct Cancer (Cholangiocarcinoma)

Condition: Cancer / Liver Cancer
Investigator: Susan Bates, MD
Status: Closed
This study is designed to evaluate the efficacy and safety of the study drug AG-120 as compared to placebo in patients with advanced cholangiocarcinoma. AG-120 blocks an abnormal form of a protein called IDH1, which is involved in cancer cell metabolism. Abnormal IDH1 causes too much of a substance called 2-HG to be produced. Researchers believe that having…
Read More

A study for patients with liver cancer using study drug RO7070179

Condition: Cancer / Liver Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to assess the safety, tolerability, and effectiveness of RO7070179 given to patients with Hepatocellular Carcinoma (HCC), a primary type of liver cancer, with normal to moderately impaired liver function. RO7070179 is given intravenously to study its effects in the treatment of liver cancer. RO7070179 is an investigational anti-…
Read More

A 5-Year Study of the Natural History and Management of Patients with Hepatocellular Carcioma (A Type of Liver Cancer)

Condition: Cancer / Liver Cancer
Investigator: Elizabeth Verna, MD
Status: Closed
Patients will be asked to participate in this research study because they have been diagnosed with hepatocellular carcinoma (HCC) which is a type of liver cancer. By doing this study, researchers hope to: Find out more about patients that have HCC including their age, race/ethnicity, and other medical conditions they may have; learn more about how…
Read More

A study for patients with biliary or gallbladder cancer using study drug DKN-01

Condition: Cancer / Liver Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
This research study is being done to see how an investigational drug called DKN-01 combined with standard cancer drugs (gemcitabine and cisplatin) works in people with biliary or gallbladder cancer. DKN-01 is an antibody that blocks the function of another protein in the body called dickkopf-1 (Dkk-1). Too much (over expression) of the Dkk-1 protein has…
Read More

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Condition: Cancer / Liver Cancer
Investigator: Yvonne Saenger, MD
Status: Closed
The purpose of this study is to learn more about TPST-1120. The aims of the study are to find out if TPST-1120 can be given safely to people, to determine a safe dose of the study drug, if it is safe when given in combination with other anti-cancer drugs, what effects the drug may have, and to learn more about how the body processes the study drug. This is…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science